Intravitreal lupeol: A new potential therapeutic strategy for noninfectious uveitis

• DOI: 10.1016/j.biopha.2021.112145
• Publication Date: 2021-09-07T20:07:17Z
• Authors: Cibele Rodrigues ...; Mayara Rodrigues ...; Brenda Fernanda M...; Vinicius Viana Pe...; Sarah Pereira de ...; Daniel Vítor Vasc...; Sílvia Ligório Fi...; Armando Silva-Cunha
• Keywords: Lupeol

Lupeol is a pentacyclic triterpene with known anti-inflammatory effects. However, its role in the treatment of noninfectious uveitis has not been explored. This work investigated activity lupeol ocular tissues vitro and vivo models. First, we evaluated effect (100 µM) on inflammatory response induced by lipopolysaccharide (LPS) retinal pigment epithelium cells (ARPE-19) measuring levels released interleukins (IL-6 IL-8). Then, action intravitreal rodent model panuveitis Mycobacterium bovis Calmette-Guérin Bacillus (BCG). Rats were submitted to electroretinography clinical analyses days 3, 7, 15 after induction. In addition, histopathological analysis, indirect quantification myeloperoxidase (MPO) N-acetylglucosaminidase (NAG) posterior segment performed. Treatment significantly decreased IL-6 IL-8 comparison untreated LPS-activated ARPE-19 cells. reduction was similar that detected treated dexamethasone. The results assay demonstrated able modulate inflammation anterior rat eyes, indicating it should be further as novel potential candidate for management uveitis.